Table 5.

Rates of thromboembolic events, cataracts and cataracts surgery—NSABP STAR Trial (P-2)

Type of Event	Events, n		Rate per 1,000			RR†	RR (95% CI)
	Tamoxifen	Raloxifene	Tamoxifen	Raloxifene	Difference*
Thromboembolic events
Thromboembolic events	202	154	3.30	2.47	0.83	0.75	0.60–0.93
Pulmonary embolism	84	68	1.36	1.09	0.27	0.80	0.57–1.11
Deep-vein thrombosis	118	86	1.93	1.38	0.55	0.72	0.54–0.95
Cataracts and Cataract Surgery
Developed cataracts during follow-up‡	739	603	14.58	11.69	2.89	0.80	0.72–0.89
Developed cataracts and had cataract surgery‡	575	462	11.18	8.85	2.33	0.79	0.70–0.90

Abbreviations: CI, confidence interval; NSABP STAR, National Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene; RR, risk ratio.

^*Rate in the tamoxifen group minus rate in the raloxifene group.

^†Risk ratio for women in the raloxifene group compared to women in the tamoxifen group.

^‡Women at risk were those with no prior history of cataracts at entry (8,341 and 8,336 tamoxifen and raloxifene participants, respectively).